FDA Adverse Event Injury Summary report: N

ESSURE

MDR report key: 7181914 · Received January 11, 2018

Report

Report Number
2951250-2018-00311
Event Type
Injury
Date Received
January 11, 2018
Date of Event
November 1, 2013
Report Date
April 20, 2020
Manufacturer
BAYER PHARMA AG
Product Code
HHS
PMA / PMN Number
P020014
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

THIS SPONTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL DISTENSION ("ABDOMINAL SWELLING") IN A 49-YEAR-OLD FEMALE PATIENT WHO HAD ESSURE INSERTED. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. ON (B)(6) 2013, THE PATIENT HAD ESSURE INSERTED. ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), THYROID DISORDER ("THYROID DISORDER"), BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE") AND PALPITATIONS ("HEART PALPITATIONS"). THE PATIENT WAS TREATED WITH SURGERY. ESSURE WAS REMOVED ON (B)(6) 2014. AT THE TIME OF THE REPORT, THE ABDOMINAL DISTENSION, THYROID DISORDER, BLOOD PRESSURE INCREASED AND PALPITATIONS OUTCOME WAS UNKNOWN. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, BLOOD PRESSURE INCREASED, PALPITATIONS AND THYROID DISORDER TO BE RELATED TO ESSURE. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON (B)(6) 2018: QUALITY-SAFETY EVALUATION OF PTC. INCIDENT: NO LOT NUMBER OR SAMPLE AVAILABLE FOR INVESTIGATION. THERE IS NO EVIDENCE THAT A DEVICE-RELATED DEFECT OR MALFUNCTION CAUSED A DEATH OR SERIOUS INJURY. IF ADDITIONAL INFORMATION BECOMES AVAILABLE IT WILL BE PROVIDED ON A SUPPLEMENTAL REPORT.

Additional Manufacturer Narrative · 0

THIS SPONTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL PAIN ("ABDOMINAL PAIN"), ABDOMINAL DISTENSION ("ABDOMINAL SWELLING / BLOATING") AND GENITAL HAEMORRHAGE ("EXCESSIVE BLEEDING") IN A 49-YEAR-OLD FEMALE PATIENT WHO HAD ESSURE INSERTED FOR FEMALE STERILISATION. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. OTHER PRODUCT OR PRODUCT USE ISSUES IDENTIFIED: DEVICE MONITORING PROCEDURE NOT PERFORMED "SHE DID NOT UNDERGO AN ESSURE CONFIRMATION TEST". THE PATIENT'S PAST MEDICAL HISTORY INCLUDED MASTECTOMY IN 2012. PREVIOUSLY ADMINISTERED PRODUCTS INCLUDED FOR AN UNREPORTED INDICATION: IUD NOS IN 2010. CONCOMITANT PRODUCTS INCLUDED ALPRAZOLAM (XANAX) AND NADOLOL SINCE 2010. ON (B)(6) 2013, THE PATIENT HAD ESSURE INSERTED. IN (B)(6) 2013, THE PATIENT EXPERIENCED ABDOMINAL PAIN (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), HYPOTHYROIDISM ("THYROID DISORDER") AND WEIGHT INCREASED ("WEIGHT GAIN"). ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), GENITAL HAEMORRHAGE (SERIOUSNESS CRITERION MEDICALLY SIGNIFICANT), BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE") AND PALPITATIONS ("HEART PALPITATIONS"). THE PATIENT WAS TREATED WITH SURGERY ((BILATERAL ESSURE MICROSURGICAL REMOVAL)) AND SURGERY ((BILATERAL ESSURE MICROSURGICAL REMOVAL)). ESSURE WAS REMOVED ON (B)(6) 2014. AT THE TIME OF THE REPORT, THE ABDOMINAL PAIN, ABDOMINAL DISTENSION AND HYPOTHYROIDISM WAS RESOLVING, THE GENITAL HAEMORRHAGE AND BLOOD PRESSURE INCREASED OUTCOME WAS UNKNOWN AND THE PALPITATIONS AND WEIGHT INCREASED HAD RESOLVED. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, ABDOMINAL PAIN, BLOOD PRESSURE INCREASED, GENITAL HAEMORRHAGE, HYPOTHYROIDISM, PALPITATIONS AND WEIGHT INCREASED TO BE RELATED TO ESSURE. DIAGNOSTIC RESULTS (NORMAL RANGES ARE PROVIDED IN PARENTHESIS IF AVAILABLE): BODY WEIGHT WAS REPORTED TO BE 52.154 KGS. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 4-AUG-2018: QUALITY-SAFETY EVALUATION OF PTC. INCIDENT NO LOT NUMBER OR SAMPLE AVAILABLE FOR INVESTIGATION. THERE IS NO EVIDENCE THAT A DEVICE-RELATED DEFECT OR MALFUNCTION CAUSED A DEATH OR SERIOUS INJURY. IF ADDITIONAL INFORMATION BECOMES AVAILABLE IT WILL BE PROVIDED ON A SUPPLEMENTAL REPORT.

Additional Manufacturer Narrative · 0

NTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL PAIN ("ABDOMINAL PAIN"), ABDOMINAL DISTENSION ("ABDOMINAL SWELLING / BLOATING") AND GENITAL HAEMORRHAGE ("EXCESSIVE BLEEDING") IN A 49-YEAR-OLD FEMALE PATIENT WHO HAD ESSURE INSERTED FOR FEMALE STERILISATION. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. OTHER PRODUCT OR PRODUCT USE ISSUES IDENTIFIED: DEVICE MONITORING PROCEDURE NOT PERFORMED "SHE DID NOT UNDERGO AN ESSURE CONFIRMATION TEST". THE PATIENT'S PAST MEDICAL HISTORY INCLUDED MASTECTOMY IN 2012. PREVIOUSLY ADMINISTERED PRODUCTS INCLUDED FOR AN UNREPORTED INDICATION: IUD NOS IN 2010. CONCOMITANT PRODUCTS INCLUDED ALPRAZOLAM (XANAX) AND NADOLOL SINCE 2010. ON (B)(6) 2013, THE PATIENT HAD ESSURE INSERTED. IN (B)(6) 2013, THE PATIENT EXPERIENCED ABDOMINAL PAIN (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), HYPOTHYROIDISM ("THYROID DISORDER") AND WEIGHT INCREASED ("WEIGHT GAIN"). ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), GENITAL HAEMORRHAGE (SERIOUSNESS CRITERION MEDICALLY SIGNIFICANT), BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE") AND PALPITATIONS ("HEART PALPITATIONS"). THE PATIENT WAS TREATED WITH SURGERY ((BILATERAL ESSURE MICROSURGICAL REMOVAL)). ESSURE WAS REMOVED ON (B)(6) 2014. AT THE TIME OF THE REPORT, THE ABDOMINAL PAIN, ABDOMINAL DISTENSION AND HYPOTHYROIDISM WAS RESOLVING, THE GENITAL HAEMORRHAGE AND BLOOD PRESSURE INCREASED OUTCOME WAS UNKNOWN AND THE PALPITATIONS AND WEIGHT INCREASED HAD RESOLVED. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, ABDOMINAL PAIN, BLOOD PRESSURE INCREASED, GENITAL HAEMORRHAGE, HYPOTHYROIDISM, PALPITATIONS AND WEIGHT INCREASED TO BE RELATED TO ESSURE. DIAGNOSTIC RESULTS (NORMAL RANGES ARE PROVIDED IN PARENTHESIS IF AVAILABLE): BODY WEIGHT WAS REPORTED TO BE 52.154 KGS. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 23-JUL-2018: PLAINTIFF FACT SHEET RECEIVED. EVENTS GENITAL BLEEDING, ABDOMINAL PAIN, WEIGHT GAIN, HYPOTHYRODISM ARE ADDED. HISTORICAL & CONCOMITANT DRUGS CONDITONS ARE ADDED. PRODUCT, PATIENT & REPORTER INFORMATION UPDATED. INCIDENT: NO LOT NUMBER OR SAMPLE AVAILABLE FOR INVESTIGATION. THERE IS NO EVIDENCE THAT A DEVICE-RELATED DEFECT OR MALFUNCTION CAUSED A DEATH OR SERIOUS INJURY. IF ADDITIONAL INFORMATION BECOMES AVAILABLE IT WILL BE PROVIDED ON A SUPPLEMENTAL REPORT.

Additional Manufacturer Narrative · 0

THIS SPONTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL PAIN ('ABDOMINAL PAIN') AND ABDOMINAL DISTENSION ('ABDOMINAL SWELLING / BLOATING') IN A 49-YEAR-OLD FEMALE PATIENT WHO HAD ESSURE INSERTED FOR FEMALE STERILISATION. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. OTHER PRODUCT OR PRODUCT USE ISSUES IDENTIFIED: DEVICE MONITORING PROCEDURE NOT PERFORMED "SHE DID NOT UNDERGO AN ESSURE CONFIRMATION TEST". THE PATIENT'S MEDICAL HISTORY INCLUDED MASTECTOMY IN 2012. PREVIOUSLY ADMINISTERED PRODUCTS INCLUDED FOR AN UNREPORTED INDICATION: IUD NOS. CONCOMITANT PRODUCTS INCLUDED ALPRAZOLAM (XANAX) AND NADOLOL SINCE 2010. ON (B)(6)2013, THE PATIENT HAD ESSURE INSERTED. IN (B)(6)2013, THE PATIENT EXPERIENCED ABDOMINAL PAIN (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED) AND HYPOTHYROIDISM ("THYROID DISORDER") AND WAS FOUND TO HAVE WEIGHT INCREASED ("WEIGHT GAIN"). ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), GENITAL HAEMORRHAGE ("EXCESSIVE BLEEDING"), PALPITATIONS ("HEART PALPITATIONS") AND SCAR ("SCAR") AND WAS FOUND TO HAVE BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE"). THE PATIENT WAS TREATED WITH SURGERY ((BILATERAL ESSURE MICROSURGICAL REMOVAL)). ESSURE WAS REMOVED ON (B)(6)2014. AT THE TIME OF THE REPORT, THE ABDOMINAL PAIN, ABDOMINAL DISTENSION AND HYPOTHYROIDISM WAS RESOLVING, THE GENITAL HAEMORRHAGE, BLOOD PRESSURE INCREASED AND SCAR OUTCOME WAS UNKNOWN AND THE PALPITATIONS AND WEIGHT INCREASED HAD RESOLVED. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, ABDOMINAL PAIN, BLOOD PRESSURE INCREASED, GENITAL HAEMORRHAGE, HYPOTHYROIDISM, PALPITATIONS, SCAR AND WEIGHT INCREASED TO BE RELATED TO ESSURE. DIAGNOSTIC RESULTS (NORMAL RANGES ARE PROVIDED IN PARENTHESIS IF AVAILABLE): BODY WEIGHT WAS REPORTED TO BE 52.154 KGS. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 20-MAR-2020: SOCIAL MEDIA RECEIVED. NEW EVENT ADDED:SCAR. BASED ON THE AVAILABLE INFORMATION, A REVIEW OF OUR COMPLAINT RECORDS AND OTHER RELEVANT DATA WILL BE CONDUCTED; ANY NEW AND REPORTABLE INFORMATION THAT BECOMES AVAILABLE FROM OUR INVESTIGATION WILL BE PROVIDED IN A SUPPLEMENTARY REPORT.

Additional Manufacturer Narrative · 0

THIS SPONTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL PAIN ('ABDOMINAL PAIN') AND ABDOMINAL DISTENSION ('ABDOMINAL SWELLING / BLOATING') IN A 49-YEAR-OLD FEMALE PATIENT WHO HAD ESSURE INSERTED FOR FEMALE STERILISATION. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. OTHER PRODUCT OR PRODUCT USE ISSUES IDENTIFIED: DEVICE MONITORING PROCEDURE NOT PERFORMED "SHE DID NOT UNDERGO AN ESSURE CONFIRMATION TEST". THE PATIENT'S MEDICAL HISTORY INCLUDED MASTECTOMY IN 2012. PREVIOUSLY ADMINISTERED PRODUCTS INCLUDED FOR AN UNREPORTED INDICATION: IUD NOS. CONCOMITANT PRODUCTS INCLUDED ALPRAZOLAM (XANAX) AND NADOLOL SINCE 2010. ON (B)(6) 2013, THE PATIENT HAD ESSURE INSERTED. IN (B)(6) 2013, THE PATIENT EXPERIENCED ABDOMINAL PAIN (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED) AND HYPOTHYROIDISM ("THYROID DISORDER") AND WAS FOUND TO HAVE WEIGHT INCREASED ("WEIGHT GAIN"). ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), GENITAL HAEMORRHAGE ("EXCESSIVE BLEEDING"), PALPITATIONS ("HEART PALPITATIONS"), SCAR ("SCAR"), FEELING COLD ("I WAS FREEZING COLD"), HYPERSOMNIA ("SLEEPING 10 TO 13 HRS A DAY"), DRY SKIN ("DRY SKIN"), ALOPECIA ("HAIR LOSS") AND IRRITABILITY ("IRRITABLE") AND WAS FOUND TO HAVE BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE"). THE PATIENT WAS TREATED WITH SURGERY ((BILATERAL ESSURE MICROSURGICAL REMOVAL)). ESSURE WAS REMOVED ON (B)(6) 2014. AT THE TIME OF THE REPORT, THE ABDOMINAL PAIN, ABDOMINAL DISTENSION AND HYPOTHYROIDISM WAS RESOLVING, THE GENITAL HAEMORRHAGE, BLOOD PRESSURE INCREASED, SCAR, FEELING COLD, HYPERSOMNIA, DRY SKIN, ALOPECIA AND IRRITABILITY OUTCOME WAS UNKNOWN AND THE PALPITATIONS AND WEIGHT INCREASED HAD RESOLVED. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, ABDOMINAL PAIN, ALOPECIA, BLOOD PRESSURE INCREASED, DRY SKIN, FEELING COLD, GENITAL HAEMORRHAGE, HYPERSOMNIA, HYPOTHYROIDISM, IRRITABILITY, PALPITATIONS, SCAR AND WEIGHT INCREASED TO BE RELATED TO ESSURE. DIAGNOSTIC RESULTS (NORMAL RANGES ARE PROVIDED IN PARENTHESIS IF AVAILABLE): BODY WEIGHT WAS REPORTED TO BE 52.154 KGS. QUALITY-SAFETY EVALUATION OF PTC: UNABLE TO CONFIRM COMPLAINT. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 23-MAR-2020: SOCIAL MEDIA RECEIVED-NEW EVENT I WAS FREEZING COLD ,SLEEPING ,DRY SKIN ,HAIR LOSS WERE ADDED. BASED ON THE AVAILABLE INFORMATION, A REVIEW OF OUR COMPLAINT RECORDS AND OTHER RELEVANT DATA WILL BE CONDUCTED; ANY NEW AND REPORTABLE INFORMATION THAT BECOMES AVAILABLE FROM OUR INVESTIGATION WILL BE PROVIDED IN A SUPPLEMENTARY REPORT.

Description of Event or Problem · 1

THIS SPONTANEOUS CASE WAS REPORTED BY A LAWYER AND DESCRIBES THE OCCURRENCE OF ABDOMINAL DISTENSION ("ABDOMINAL SWELLING") IN A (B)(6) FEMALE PATIENT WHO HAD ESSURE INSERTED. THE OCCURRENCE OF ADDITIONAL NON-SERIOUS EVENTS IS DETAILED BELOW. ON (B)(6) 2013, THE PATIENT HAD ESSURE INSERTED. ON AN UNKNOWN DATE, THE PATIENT EXPERIENCED ABDOMINAL DISTENSION (SERIOUSNESS CRITERIA MEDICALLY SIGNIFICANT AND INTERVENTION REQUIRED), THYROID DISORDER ("THYROID DISORDER"), BLOOD PRESSURE INCREASED ("INCREASED BLOOD PRESSURE") AND PALPITATIONS ("HEART PALPITATIONS"). THE PATIENT WAS TREATED WITH SURGERY. ESSURE WAS REMOVED ON (B)(6) 2014. AT THE TIME OF THE REPORT, THE ABDOMINAL DISTENSION, THYROID DISORDER, BLOOD PRESSURE INCREASED AND PALPITATIONS OUTCOME WAS UNKNOWN. THE REPORTER CONSIDERED ABDOMINAL DISTENSION, BLOOD PRESSURE INCREASED, PALPITATIONS AND THYROID DISORDER TO BE RELATED TO ESSURE. MOST RECENT FOLLOW-UP INFORMATION INCORPORATED ABOVE INCLUDES: ON 5-JAN-2018: REPORTERS, PATIENT DETAILS AND PRODUCT STOP DATE WERE ADDED. EVENT ¿SEVERE AND PERMANENT INJURIES¿ UPDATED WITH NEW EVENTS ¿ABDOMINAL SWELLING, THYROID DISORDER, INCREASED BLOOD PRESSURE AND HEART PALPITATIONS¿. ESSURE REMOVAL DATE PROVIDED: CASE IS NOW CONSIDERED INCIDENT. ESSURE LEGAL MANUFACTURER HAS CHANGED FROM BAYER HEALTHCARE, LLC, MILPITAS TO BAYER PHARMA AG, BERLIN, AND THIS REPORT IS BEING SUBMITTED AS A FOLLOW UP TO A PREVIOUS REPORT SUBMITTED UNDER THE FORMER LEGAL MANUFACTURER. REPORT TYPE ¿INITIAL¿ INDICATES HERE INITIAL SUBMISSION BY THE NEW LEGAL MANUFACTURER ONLY. INCIDENT NO LOT NUMBER OR SAMPLE AVAILABLE FOR INVESTIGATION. THERE IS NO EVIDENCE THAT A DEVICE-RELATED DEFECT OR MALFUNCTION CAUSED A DEATH OR SERIOUS INJURY. IF ADDITIONAL INFORMATION BECOMES AVAILABLE IT WILL BE PROVIDED ON A SUPPLEMENTAL REPORT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
26409 ESSURE TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE HHS BAYER PHARMA AG ESS305

Patients

Seq Age Sex Outcome Treatment
1 49 YR Other| R NADOLOL| NADOLOL| NADOLOL| NADOLOL| XANAX| XANAX| XANAX| XANAX